Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study

被引：0
|
作者：
Shi, Y-K. [1 ]
Gao, L. [2 ]
Tian, Y. [3 ]
Chen, J. [4 ]
Wang, J. [3 ]
Bai, C. [5 ]
Li, X. [6 ]
Su, H. [7 ]
Liu, Z. [8 ]
机构：
[1] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Gansu Prov Canc Hosp, Dept Radiotherapy, Lanzhou, Peoples R China
[3] Gansu Prov Canc Hosp, Head & Neck Serv, Lanzhou, Peoples R China
[4] Cent South Univ, Xiangya Med Sch, Hunan Canc Hosp, Dept Thorac Surg 1, Changsha, Peoples R China
[5] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[7] Fourth Mil Med Univ, Tangdu Hosp, Oncol Dept, Xian, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Oncol, Dept Head & Neck Serv, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908P
引用
收藏
页码：S806 / S806
页数：1
相关论文
共 50 条
  • [41] Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Jove, M.
    Brana, I.
    Oliva Bernal, M.
    Hernando-Calvo, A.
    Erasun Lecuona, C.
    Assaf Pastrana, J. D.
    Bazan Peregrino, M.
    Mato-Berciano, A.
    Maliandi, M. V.
    Torres-Manjon, S.
    Martinez De Villareal, J.
    Real, F. X.
    Nuciforo, P. G.
    Alemany, R.
    Capella, G.
    Blasi, E.
    Blasco, C.
    Cascallo Piqueras, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1112 - S1112
  • [42] Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC)
    Brooks, H. D.
    Glisson, B.
    Lu, C.
    Sabichi, A.
    Johnson, F.
    Ginsberg, L.
    Bekele, B.
    Papadimitrakopoulou, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [44] Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
    Iglesias Docampo, L.
    Baste Rotllan, N.
    Oliva Bernal, M.
    Carral Maseda, A.
    Perez Segura, P.
    Medina Colmenero, A.
    Cirauqui Cirauqui, B.
    Arrazubi Arrula, V.
    Martinez Trufero, J.
    Gutierrez Calderon, V.
    Garcia Castano, A.
    Rubio-Casadevall, J.
    Basterretxea, L.
    Alvarez Cabellos, R.
    del Barco Morillo, E.
    Bruixola, G.
    Flor, M. J.
    Assaf Pastrana, J. D.
    Caballero Daroqui, J.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S624 - S624
  • [45] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tseng, JE
    Glisson, BS
    Khuri, FR
    Shin, DM
    Myers, JN
    El-Naggar, AK
    Roach, JS
    Ginsberg, LE
    Thall, PF
    Wang, XM
    Teddy, S
    Lawhorn, KN
    Zentgraf, RE
    Steinhaus, GD
    Pluda, JM
    Abbruzzese, JL
    Hong, WK
    Herbst, RS
    CANCER, 2001, 92 (09) : 2364 - 2373
  • [47] Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Gedlicka, C
    Formanek, M
    Selzer, E
    Burian, M
    Kornfehl, J
    Fiebiger, W
    Cartellieri, M
    Marks, B
    Kornek, GV
    ONCOLOGY, 2002, 63 (02) : 145 - 150
  • [48] Phase II study of dasatinib in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma
    Stabile, Laura P.
    Egloff, Ann Marie
    Zhou, Pei
    Gooding, William E.
    Grandis, Jennifer R.
    Bauman, Julie E.
    CANCER RESEARCH, 2016, 76
  • [49] Phase II study of cetuximab and lenalidomide in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Taylor, Rodney J.
    Saloura, Vassiliki
    Wong, Richard
    Goloubeva, Olga
    Silpino, Lorna
    de Souza, Jonas
    Seiwert, Tanguy
    Vokes, Everett
    Cohen, Ezra
    Villaflor, Victoria
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [50] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
12345